Bristol-Myers Squibb Company
BMYHealthcareNASDAQDrug Manufacturers - General
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Bristol-Myers Squibb Company focuses on Drug Manufacturers - General services and products. Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. At a $125.59B market cap, Bristol-Myers Squibb Company ranks as a large-cap company within healthcare. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications.
Market Cap
$125.59B
Beta
0.18
P/E (TTM)
13.54
P/E (Fwd)
9.31
EPS (TTM)
$4.54
EPS (Fwd)
$6.61
ROE
46.6%
ROA
10.7%
Cash
$11.07B
Total Debt
$45.05B
Free CF
$8.11B
52W Change
40.3%
Annual Financials
Cash vs Debt
Where BMY stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, BMY finished 0.68% below its 150-day moving average ($59.23) and 0.55% above its 200-day moving average ($58.51). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is BMY overbought or oversold?
At the October 20, 2026 close, BMY's RSI(14) was 37.6, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
On the balance sheet, BMY has $11.07B in cash with $45.05B in obligations. The ability to service this debt comfortably depends on continued operational cash generation. Annual free cash flow of $8.11B supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. Return on equity stands at 46.6%, which is exceptionally high for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Return on assets of 10.7% further supports the picture of efficient asset utilization. Revenue has been relatively flat, moving from $46.16B (2022) to $48.20B (2025).
With a beta below 0.7, Bristol-Myers Squibb Company typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Bristol-Myers Squibb Company and its sector.